Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EBITDA: 2019-2024

Historic EBITDA for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to -$338.5 million.

  • Relay Therapeutics' EBITDA rose 12.77% to -$73.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$299.6 million, marking a year-over-year increase of 11.70%. This contributed to the annual value of -$338.5 million for FY2024, which is 2.04% down from last year.
  • Per Relay Therapeutics' latest filing, its EBITDA stood at -$338.5 million for FY2024, which was down 2.04% from -$331.7 million recorded in FY2023.
  • In the past 5 years, Relay Therapeutics' EBITDA registered a high of -$52.7 million during FY2020, and its lowest value of -$365.0 million during FY2021.
  • Moreover, its 3-year median value for EBITDA was -$331.7 million (2023), whereas its average is -$323.4 million.
  • In the last 5 years, Relay Therapeutics' EBITDA rose by 29.75% in 2020 and then crashed by 593.00% in 2021.
  • Relay Therapeutics' EBITDA (Yearly) stood at -$52.7 million in 2020, then tumbled by 593.00% to -$365.0 million in 2021, then increased by 17.86% to -$299.8 million in 2022, then declined by 10.64% to -$331.7 million in 2023, then decreased by 2.04% to -$338.5 million in 2024.